Naja, K.; Salami, A.; El Shamieh, S.; Fakhoury, R.
rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. J. Pers. Med. 2020, 10, 53.
https://doi.org/10.3390/jpm10020053
AMA Style
Naja K, Salami A, El Shamieh S, Fakhoury R.
rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. Journal of Personalized Medicine. 2020; 10(2):53.
https://doi.org/10.3390/jpm10020053
Chicago/Turabian Style
Naja, Khaled, Ali Salami, Said El Shamieh, and Rajaa Fakhoury.
2020. "rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study" Journal of Personalized Medicine 10, no. 2: 53.
https://doi.org/10.3390/jpm10020053
APA Style
Naja, K., Salami, A., El Shamieh, S., & Fakhoury, R.
(2020). rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. Journal of Personalized Medicine, 10(2), 53.
https://doi.org/10.3390/jpm10020053